极早产儿氧浓度自动控制与手动控制的临床结局比较:多中心随机对照优效性试验
该多中心平行组随机对照优效性试验纳入23+0至27+6周极早产儿,比较自动闭环FiO2控制(FiO2-C)与常规手动控制的临床结局。FiO2-C未改善新生儿临床结局,但长期应用以减少护理工作量可能安全。
要点
- 极早产儿使用FiO2-C与常规手动控制相比,主要复合终点发生率无显著差异。
- 死亡、NEC、BPD和严重ROP等次要终点两组发生率相似。
- FiO2-C未改善临床结局,但长期应用以减少护理工作量可能安全。
核心结论
- FiO2-C未改善极早产儿新生儿临床结局。
- 长期应用FiO2-C以减少护理人员工作量可能被认为是安全的。
- FiO2-C算法应在常规应用前进行测试。
研究设计与样本
- 多中心、平行组、随机对照、优效性试验,在32个新生儿重症监护病房开展。
- 纳入胎龄23+0至27+6周的极早产儿,随机分为FiO2-C组(n=539)或常规手动控制组(n=543)。
- 主要分析纳入有完整主要结局数据的意向性治疗人群。
- 试验因招募不佳提前终止。
主要发现
- 死亡率FiO2-C组536例中48例(9%) vs 常规组541例中50例(9%)。
- 坏死性小肠结肠炎发生率FiO2-C组538例中27例(5%) vs 常规组542例中36例(7%)。
- 支气管肺发育不良发生率FiO2-C组486例中104例(21%) vs 常规组485例中110例(23%)。
临床怎么用
- FiO2-C不应视为改善极早产儿临床结局的干预措施。
- 在常规应用FiO2-C算法前,需先进行测试验证。
局限性
- 试验因招募不佳提前终止。
- 报告了4例与软件功能相关的严重事件,但未对受累婴儿造成明显伤害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extremely preterm infants require respiratory support with supplemental oxygen and have frequent hypoxaemic episodes. These episodes, and exposure to inadequately high concentrations of oxygen, are associated with major complications and death. Closed-loop automated control of the fractional concentration of oxygen in inspired air (FiO2-C) reduces the time below and above the target range for the pulse oximeter oxygen saturation (SpO2) and caregivers' workload. We aimed to study whether FiO2-C during respiratory support versus routine manual control might also improve clinical outcomes. METHODS: This multicentre, parallel-group, randomised, controlled, superiority trial was done in 32 neonatal intensive care units in China, Germany, the Netherlands, and the UK. Infants born at 23+0 weeks to 27+6 weeks postmenstrual age were included and randomly assigned to FiO2-C or routine manual care stratified within centres by postmenstrual age at birth and sex. FiO2-C was provided in addition to routine manual control of FiO2 using infant ventilators. The composite primary endpoint was death, necrotising enterocolitis, or bronchopulmonary dysplasia up to 36 weeks postmenstrual age, or severe retinopathy of prematurity by 44 weeks postmenstrual age. Secondary endpoints were the components of the primary endpoint and the maximum retinopathy of prematurity severity score in either eye on the International Neonatal Consortium Retinopathy of Prematurity Activity Scale. The trial was stopped early because of poor recruitment. The primary analysis included the intention-to-treat population with non-missing primary outcome data. This trial was registered with ClinicalTrials.gov (NCT03168516) and is closed. FINDINGS: Between July 1, 2018, and Oct 31, 2023, 1082 infants were enrolled and randomly assigned to the FiO2-C group (n=539) or routine manual control group (n=543). Median postmenstrual age was 26+1 weeks (IQR 24+6-27+1). 557 (51%) of 1082 infants were male and 525 (49%) were female. The primary endpoint occurred in 206 (39%) of 534 infants in the FiO2-C group versus 222 (41%) of 538 infants in the routine manual control group (adjusted odds ratio 0·90, 97·5% CI 0·65-1·24; p=0·47). Rates of death (48 [9%] of 536 infants vs 50 [9%] of 541 infants), necrotising enterocolitis (27 [5%] of 538 vs 36 [7%] of 542), bronchopulmonary dysplasia (104 [21%] of 486 vs 110 [23%] of 485), and severe retinopathy of prematurity (86 [18%] of 491 vs 95 [19%] of 496) were also similar between groups. The maximum retinopathy of prematurity severity score was similar between groups (median 7 [IQR 0-9]; p=0·24). Overall, 197 serious adverse events were reported in the FiO2-C group and 192 in the routine manual control group, with no evidence of harm related to the intervention. Postnatal age at death and primary causes of death were similar in both groups. Four serious incidents related to software function without apparent harm to affected infants were reported. INTERPRETATION: FiO2-C did not improve neonatal clinical outcomes. The long-term application of FiO2-C to reduce caregivers' workload might be considered safe. FiO2-C algorithms should be tested before routine application. FUNDING: German Federal Ministry of Education and Research.
引用
- Franz AR, Maiwald CA, Niemarkt HJ, et al. Automatic versus manual control of oxygen and neonatal clinical outcomes in extremely preterm infants: a multicentre, parallel-group, randomised, controlled, superiority trial. Lancet Child Adolesc Health. 2026. PMID: 41679888. doi:10.1016/S2352-4642(25)00351-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。